NurseJet
Back to Discover
Systematic ReviewResearchMedication SafetyPatient Education

Selective D1/D5 partial agonists improved Parkinson motor outcomes but increased adverse effects

Neurological sciences (PubMed)Aug 15, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A GRADE-assessed meta-analysis found that selective D1/D5 dopamine partial agonists improved motor outcomes in early and levodopa-treated Parkinson disease, while adverse effects and treatment discontinuation were more frequent than with placebo.

What NurseJet pulled from the source

Seven randomized double-blind trials included 1,540 participants, with five entering quantitative synthesis. Tavapadon improved the combined MDS-UPDRS Parts II and III score and added 1.09 hours of good ON-time per day, but nausea, dizziness, overall adverse events, and discontinuation were more common.

Why this matters for nurses

Neurology nurses track mobility, daily function, ON/OFF patterns, adherence, falls, and treatment intolerance. The findings highlight potential motor benefit while reinforcing that dizziness, nausea, discontinuation, and uncertain neuropsychiatric advantages require structured assessment and medication follow-up.

Bedside takeaway

Track motor benefit and tolerability together; placebo-controlled improvement does not establish superiority to other dopamine agonists.

How This Applies in Practice

Use this when: Monitoring a patient with Parkinson disease who has been prescribed a selective D1/D5 dopamine partial agonist.

On your shift

  • Document baseline mobility, activities of daily living, ON/OFF timing, falls, cognition, behavior, sleepiness, nausea, dizziness, and adherence.
  • Trend motor function and good ON-time alongside adverse effects, orthostatic symptoms, fall risk, and reasons for missed doses or discontinuation.
  • Use teach-back for the prescribed schedule and findings that require contacting the neurology team, including behavior change or unsafe sleepiness.
Keep in mind: The evidence is short-term and placebo-controlled and does not authorize independent medication changes. Follow the neurology protocol, facility medication policy, and provider orders.

Key takeaways

  • The review included seven placebo-controlled trials with 1,540 participants; five trials contributed to quantitative synthesis.
  • In early disease, tavapadon improved the combined MDS-UPDRS Parts II and III score by 10.55 points versus placebo across two trials.
  • In levodopa-treated participants with motor fluctuations, good ON-time increased by 1.09 hours per day across two trials.
  • No outcome had high-certainty evidence, no trial used an active comparator, and no trial followed participants beyond 27 weeks.

Practice implications

  • For a prescribed selective D1/D5 partial agonist, establish baseline motor and functional status, track ON/OFF timing and falls, and assess nausea, dizziness, somnolence, behavior, and adherence. Escalate suspected adverse effects or functional decline without independently changing therapy.

Limitations & cautions

  • Only five of seven trials entered quantitative synthesis, no outcome reached high certainty, no study used an active comparator, and follow-up did not exceed 27 weeks. Evidence for impulse-control disorders and somnolence was very low certainty, so an advantage over D2/D3 agonists remains untested.
  • AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Neurological sciences (PubMed)

Neurological sciences (PubMed). "Efficacy, safety and certainty of evidence for selective D1/D5 dopamine receptor partial agonists in Parkinson's disease: a systematic review, meta-analysis and GRADE assessment".

Open original source

https://pubmed.ncbi.nlm.nih.gov/42601529/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Neurosurgical review (PubMed)

A systematic review and meta-analysis of 14 studies comprising 7,981 patients found extending single-agent antibiotic prophylaxis beyond one day did not reduce postoperative meningitis after endoscopic endonasal skull base surgery, whereas intraoperative CSF leak significantly increased infection risk.

Med-SurgAI summaryReview source

Trauma, violence & abuse (PubMed)

A systematic review and meta-analysis of 20 emergency department studies encompassing 7,498 women found intimate partner violence was associated with a three-fold increased risk of suicide attempt, with psychological violence showing a stronger association than physical violence.

EmergencyPsychAI summaryReview source

Anesthesia and analgesia (PubMed)

A meta-analysis of 25 randomized controlled trials with 3,344 surgical patients found perioperative ketamine and esketamine were associated with reduced postoperative delirium between days 2 and 7, but significantly increased postoperative dizziness.

GeriatricsMed-SurgAI summaryReview source